Literature DB >> 25822038

Diagnostic evaluation and risk factors for drug allergies in children: from clinical history to skin and challenge tests.

Tugba Arikoglu1, Gulen Aslan, Sehra Birgul Batmaz, Gulcin Eskandari, Ilter Helvaci, Semanur Kuyucu.   

Abstract

BACKGROUND: Parent or self-reported drug allergy claims frequently overestimate the real incidence of hypersensitivity reactions. A detailed and algorithmic diagnostic evaluation of drug reactions may allow a proper diagnosis.
OBJECTIVE: The aim of this study was to determine the confirmation rates and risk factors for confirmed allergic drug reactions in children.
SETTING: Mersin University Hospital in Turkey.
METHOD: The study consisted of children between ages of 8 months and 18 years with the history of suspected drug allergy as reported by the clinician or the patients. Parents were interviewed by a clinician to complete questionnaires that included questions about demographic data and characteristics of index drug reaction. Immediate reactions (IRs) were assessed with immediate-reading skin prick (SPT) and intradermal tests (IDT). Nonimmediate reactions (NIRs) were assessed with SPT, both early and delayed reading of IDT and patch tests. In case of negative skin tests, drug provocation tests were performed. The possible risk factors for confirmed drug allergy in univariate analysis (p < 0.1) were entered into the multivariate logistic regression analysis to determine independent predictors. MAIN OUTCOME MEASURE: (1) Confirmation rates of drug allergy (2) Risk factors related to confirmed drug allergy in children.
RESULTS: We evaluated a total of 180 suspected drug allergy reactions in 97 children, mainly to antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs) and anticonvulsants. Among all suspected allergic drug reactions, 97 (53.9 %) were immediate type and 83 (46.1 %) were non-immediate type. The average time interval between the reaction and allergologic work-up was 5 months. Drug allergy confirmation rates were 30.1 % for beta-lactams, 27.2 % for non-betalactams, 21.1 % for NSAIDs and 30 % for anticonvulsants. Eight of 54 confirmed NIRs showed positivity on immediate skin tests. Regulatory T cells, TGF-β and IL-10 levels were not different between groups with and without confirmed drug allergy. A strong family and personal history of drug allergy were found to be significantly related to the confirmed allergic drug reactions.
CONCLUSION: Parent or self-reported drug allergy should be evaluated with a standardized diagnostic work-up before strict prohibitions are made. In addition, family and personal histories of drug allergy were significant risk factors related to allergic drug reactions in children.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25822038     DOI: 10.1007/s11096-015-0100-9

Source DB:  PubMed          Journal:  Int J Clin Pharm


  40 in total

1.  Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Stephen Tomlin; Wolfgang Rascher; Antje Neubert
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.

Authors:  Hai-Ling Qiao; Qiang Wen; Na Gao; Xin Tian; Lin-Jing Jia
Journal:  Eur J Clin Pharmacol       Date:  2007-01-16       Impact factor: 2.953

3.  Allergy to antibiotics in children: Perception versus reality.

Authors:  Jm Langley; S Halperin
Journal:  Can J Infect Dis       Date:  2002-05

4.  Immediate-type drug hypersensitivity and associated factors in a general population.

Authors:  E Kurt; A U Demir; O Cadirci; H Yildirim; T Pinar Eser
Journal:  Allergol Immunopathol (Madr)       Date:  2010-08-01       Impact factor: 1.667

5.  Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge.

Authors:  M E Pichichero; D M Pichichero
Journal:  J Pediatr       Date:  1998-01       Impact factor: 4.406

6.  Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests.

Authors:  C Ponvert; Y Perrin; A Bados-Albiero; M Le Bourgeois; C Karila; C Delacourt; P Scheinmann; J De Blic
Journal:  Pediatr Allergy Immunol       Date:  2011-03-30       Impact factor: 6.377

7.  Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.

Authors:  M Blanca; M J Torres; J J García; A Romano; C Mayorga; E de Ramon; J M Vega; A Miranda; C Juarez
Journal:  J Allergy Clin Immunol       Date:  1999-05       Impact factor: 10.793

8.  Adverse drug events in general practice patients in Australia.

Authors:  Graeme C Miller; Helena C Britth; Lisa Valenti
Journal:  Med J Aust       Date:  2006-04-03       Impact factor: 7.738

Review 9.  Provocation tests in diagnosing drug hypersensitivity.

Authors:  Philippe-Jean Bousquet; Francesco Gaeta; Laure Bousquet-Rouanet; Jean-Yves Lefrant; Pascal Demoly; Antonino Romano
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases.

Authors:  Amale Hassani; Claude Ponvert; Chantal Karila; Muriel Le Bourgeois; Jacques De Blic; Pierre Scheinmann
Journal:  Eur J Dermatol       Date:  2008-08-08       Impact factor: 3.328

View more
  3 in total

Review 1.  Antibiotic Allergy in Pediatrics.

Authors:  Allison Eaddy Norton; Katherine Konvinse; Elizabeth J Phillips; Ana Dioun Broyles
Journal:  Pediatrics       Date:  2018-05       Impact factor: 7.124

2.  Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report.

Authors:  Jitendra H Vaghela; Vivek Nimbark; Manish Barvaliya; Hita Mehta; Bhavesh Chavada
Journal:  Drug Saf Case Rep       Date:  2018-05-21

3.  Altered vaginal microbiome and relative co-abundance network in pregnant women with penicillin allergy.

Authors:  Xiaohua Li; Jun Luo; Chuan Nie; Qingxia Li; Xiaofeng Sun; Hongping Li; Yong Zhang
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-09       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.